-

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment, and violations of the Securities Exchange Act of 1934. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.

If you suffered a loss as a result of Vanda's misconduct, click here.

Vanda Pharmaceuticals Used its Drugs for Off-Label Purposes

For years, Vanda and its officers hid that Vanda was involved in a fraudulent scheme that included violations of federal Medicare, Medicaid, and Tricare programs and that Vanda's promotional materials were false and misleading, garnering scrutiny from the FDA. Specifically, Vanda schemed to promote its drugs Fanapt and Hetlioz for "off-label" uses in addition to other prohibited promotional strategies. Vanda's executives and officers knew about the prohibited promotional strategies and actively participated in the fraudulent activity. Vanda also issued misleading statements regard tradipitant's clinical trials with the FDA. When the truth was revealed, Vanda's stock declined over 5% and has slipped even more, now trading at just around $11.00. As a result of this conduct, Vanda is facing significant liability from a Qui Tam lawsuit and has already incurred substantial expenses in its investigation. Vanda has also been named as a defendant in a securities class action lawsuit, causing further damage to the company.

Vanda Pharmaceuticals Inc. (VNDA) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. For be notified if a class action against Vanda Pharmaceuticals settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges LINC Stockholders Who Lost Money Investing in Lincoln Education Services Corporation to Contact the Firm for Information About Leading the Class Action 

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Lincoln Education Services Corporation (NASDAQ: LINC) securities between May 11, 2026 and August 9, 2026 (the "Class Period"). Lincoln provides various career-oriented postsecondary education services to high school graduates and working adults in the United States.The complaint alleges that Lincoln misled invest...

Robbins LLP Urges ASTS Stockholders Who Lost Money Investing in AST SpaceMobile, Inc. to Contact the Firm About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired AST SpaceMobile, Inc. (NASDAQ: ASTS) securities between March 4, 2025 and July 15, 2026, inclusive (the Class Period). AST, together with its subsidiaries, designs and develops the constellation of BlueBird (“BB”) satellites in the U.S. The Company provides a cellular broadband network in space for direct access...

Robbins LLP Urges BIDU Stockholders Who Lost Money Investing in Baidu, Inc. to Contact the Firm for Information About the Class Action  

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Baidu, Inc. (NASDAQ: BIDU) securities, including call options, between November 18, 2025 and August 17, 2026, inclusive (the "Class Period"). Baidu is a Chinese technology company that operates the most popular internet search engine in China.The complaint alleges that Baidu, Inc. overstated the ability of its AI...
Back to Newsroom